TR Matrix™  Technical Page

TR Matrix™ is a resorbable medical device bioscaffold composed of a proprietary, non-immunogenic polymer designed to mimic tertiary embryonic connective tissue.  TR Matrix's unique, open polar structure reveals natural amino acid sequences not found in traditional bioscaffolds.  NO OTHER SCAFFOLDS have this critical structural property.  Host cells bind to TR Matrix™ and recognize these amino acid sequences resulting in activation of physiologic tissue repair and induce fetal like repair mechanisms.

Advanced BioScaffold Properties: 
Non-Immunogenic: Novel stucture avoids immune reactions, improving tissue integration.  
Open-Polar Structure: Embryonic-like structure exposes natural amino acid sequences to promote physiological tissue repair. 
Multi-Tissue Compliance: Studied in a variety of tissues including bone, skin, tendon, etc.
Cost Effective:  Very cost effective compared to growth factors and/or cell based therapies.   

Product Formats:  TR Matrix™ has been developed into two convenient formats, a ThermoGEL (5ml) and Lyophilized GEL (1 gm).  Products are sterile and manufactured according to GMP standards.  These two formats give the veterinarian options and allow for precision in application for hard and soft tissue repair. 


TR Matrix Technical References:

Publications

Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats.  Ravin AG, Olbrich KC, Levin LS, Usala A-L and Klitzman B. J Biomed Mater Res. 58(3): 313-8, 2001.

Initial report of the use of injectable porcine collagen matrix to stimulate healing of diabetic foot wounds in humans.  Marston W, Usala A, Hill RS, Mendes R and Minsley M-A. Wound Repair and Regeneration. 2005, 13:243-247.

Scientific Presentations

Rapid induction of vasculogenesis and wound healing using a novel injectable connective tissue matrix. Usala A-L, Klann R, Bradfield J, Ray S, Hill R, De la Sierra D, Usala M, Metzger M, and Olson G.  Diabetes 49 (Suppl. 1): A395, 2000.

Long-term neovascularization and capsule thickness surrounding implants coated with hydrogel matrices.  Presented at the North Carolina Tissue Engineering Interest Group Meeting, July 7, 1999, North Carolina Biotechnology Center, Research Triangle Park, NC.

Induction of fetal-like wound repair mechanisms in vivo with a novel matrix scaffolding.  Usala A-L, Dudek R, Lacy S, Olson J, Penland S, Sutton J, Ziats N, and Hill R.  Diabetes 50 (Suppl. 2): A488, 2001.

Repairing skin wounds through tissue engineering.  Hill, RS.  Invited Speaker, SMI Tissue Engineering Conference, London, November 14th, 2001.

Decreased scarring of surgical wounds in vivo following treatment with a novel biopolymer E-Matrix™.  Lacy SA, Penland SL, Sutton JC, Usala A-L, Olson J, Harris G and Hill RS.  The 2nd International Conference and Exposition of Engineering Tissue Growth, March 19-21, 2002   Pittsburgh, PA.

A novel hydrogel copolymer reduces scar formation and increases TGFß3 gene expression. Klann R, Lloyd W, Lacy S, Sutton J, Usala A and Hill R. Platform Presentation at the 15th Annual Symposium on Advanced Wound Care, April 27-30, 2002   Baltimore, MD.

Initial report of the use of injectable porcine collagen matrix to stimulate healing of diabetic foot wounds in humans.  Marston W, Usala A, Hill RS, Mendes R and Minsley M-A. Platform presentation at the 15th Annual Symposium on Advanced Wound Care, April 27-30, 2002   Baltimore, MD

E-Matrix™: a substrate for tissue engineering. Hill RS, Klann RC, Lamberti FV, Lacy S, Lloyd WH, Sutton J and Penland S.  Presented at North Carolina Tissue Engineering Interest Group Meeting, June 7, 2002  NC Biotechnology Center, RTP, NC

DNA microarray analysis of gene expression changes in human skin fibroblasts treated with E-Matrix™, a novel wound healing hydrogel formulation. Klann RC, Lloyd WH, Sutton JC and Hill RS. Presented at, NIDDK/NIAID/NHLIB Workshop, Advanced Topics in Microarray Analysis, January 22, 2003   Bethesda, MD

Regenerative tissue scaffoldings.  Hill R. Invited Speaker, Bioprocessing & Process Development Group Seminar, North Carolina Biotech Center, March 20, 2003.

Selective Induction of TGF Beta 3 as a Marker for Scarless Regenerative Healing in the Skin. Klann RC, Lloyd B, Sutton J and Hill R. Presented at North Carolina Tissue Engineering Interest Group Meeting, June 20, 2003  NC Biotechnology Center, RTP, NC.

E-Matrix™: A Fetal-Like Extracellular Scaffold for Tissue Integration. Klann RC, Lloyd WH, Sutton JC and Hill RS. Presented at the Gordon Research Conference on Biomaterials and Tissue Engineering, Plymouth, NH, July 20-25, 2003.

Fetal-like Tissue Scaffolding as a Substrate for Regenerative Tissue Repair. Klann RC. Invited Speaker, East Carolina University Brody School of Medicine, Department of Anatomy and Cell Biology Seminar Series. November 12, 2003.

A Novel Biomatrix Stimulates Healing in Rabbit Ulna Critical Size Defects.  Hill, RS, Enterline, D, and Shih, M-S.  Presentated at 31st European Symposium on Calcified Tissues, 4-6 June 2004.

A Novel Biopolymer Matrix Induces BMP-2 Production and Stimulates Bone Repair in Critical Size Ulnar Defects. Klann, Richard C., Lloyd, William H., Sutton, Jereme C., Shih, Mei-Shu, Enterline, Dave S., and Hill, Ronald S. Platform presentation, Regenerate 2004, Seattle, WA, June 9-12, 2004.

Tissue-specific Response to a Fetal-like Extracellular Matrix:  Differential In vitro Gene Expression Associated with Regenerative Wound Repair. William Lloyd, Rich Klann, Jereme Sutton, and Ron Hill. Presented at North Carolina Tissue Engineering Interest Group Meeting, September 30, 2004  NC Biotechnology Center, RTP, NC.

A Pilot Clinical Study for the Treatment of Diabetic Foot Ulcers with an Injectable Bioactive Co-Polymer.  J.R. Hanft, Blume, PA, Dardik, P, Gordon, I, Hill, RS, Landsman, AI,  Lipkin, S, Marston, WA, Morgan, J, Orgill, D and Tallis, A.  Platform Presentation at the 2005 SAWC, San Diego, CA, April, 2005.

A Pilot Randomized Study of the Treatment of Diabetic Foot Ulcers with a Bioactive Co-Polymer, E-Matrix.  Marston, WA, Blume, PA, Dardik, P, Gordon, I, Hanft, JR, Hill, RS, Landsman, AI,  Lipkin, S, Morgan, J, Orgill, D and Tallis, A.  Platform Presentation at the 2005 Wound Healing Society Meeting, Chicago, IL, May 18-21, 2005.

Treatment of Diabetic Foot Ulcers with a Bioactive Co-Polymer, E-Matrix.  Ronald S. Hill, Presented at the 7th Annual NIH SBIR/STTR Conference, National Institutes of Health, Bethesda, MD, July 28-29, 2005.

Biopolymers for Tissue Regeneration: E-Matrix. Francis Lamberti, Rich Klann, Billy Lloyd, Jereme Sutton, Melissa Funke, Dave Schwartz and Ron Hill. Presentated at North Carolina Tissue Engineering Interest Group Meeting, October 14, 2005  NC Biotechnology Center, RTP, NC.

Preservation of Bioactivity Post-Lyophilization of E-Matrix Biopolymer for Regenerative Wound Repair. Billy Lloyd, Jereme Sutton, Francis Lamberti, Rich Klann and Ron Hill. Presented at North Carolina Tissue Engineering Interest Group Meeting, October 14, 2005  NC Biotechnology Center, RTP, NC.

Enhancement of BMP-2, Bone Sialoprotein and Osteopontin Gene Expression in Human Mesenchymal Stem Cells Exposed to a Bioactive Hydrogel, E-Matrix™. Klann, Richard C., Lloyd, William H., and Hill, Ronald S. Pesentated at Regenerate 2006, Pittsburgh, PA, April 23-26, 2006.

Copyright . TR BioSurgical, LLC. All rights reserved.